The Pharmacokinetic-Pharmacodynamic Model of Azithromycin for Lipopolysaccharide-Induced Depressive-Like Behavior in Mice

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Hao, Kun ^a   Qi, Qu ^a   Hao, Haiping ^a   Wang, Guangji ^a   Chen, Yuancheng ^b   Liang, Yan ^a   Xie, Lin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; KYNURENINE;

ADVERSE OUTCOME; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG RESPONSE; FORCED SWIMMING TEST; IC 50; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BEHAVIOR, ANIMAL; DEPRESSION; LIPOPOLYSACCHARIDES; MICE; STRESS, PHYSIOLOGICAL;

MUS;

EID: 84872852856     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054981     Document Type: Article

References (55)

1. Pitossi F, del Rey A, Kabiersch A, Besedovsky H, (1997) Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J Neurosci Res 48: 287-298.
2. Capuron L, Dantzer R (2003) Cytokines and depression: the need for a new paradigm. Brain Behav Immun (Suppl 1): 119-124.
3. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, et al. (2002) Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26: 643-652.
4. O'Connor JC, Lawson MA, André C, Moreau M, Lestage J, et al. (2009) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14: 511-522.
5. Popov A, Abdullah Z, Wickenhauser C, Saric T, Driesen J, et al. (2006) Indoleamine dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J Clin Invest 116: 3160-3170.
6. Booij L, Van der Does AJ, Riedel WJ, (2003) Monoamine depletion in psychiatric and healthy populations:review. Mol Psychiatry 8: 951-973.
7. Moreau M, Lestage J, Verrier D, Mormede C, Kelley KW, et al. (2005) Bacille Calmette-Guerin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice. J Infect Dis 192: 537-544.
8. Frenois F, Moreau M, O'Connor J, Lawson M, Micon C, et al. (2009) Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 32: 516-531.
9. Guillemin GJ, Smythe G, Takikawa O, Brew BJ, (2005) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49: 15-23.
10. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR, (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56: 2007-2017.
11. Muller N, Schwarz MJ, (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12: 988-1000.
12. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, et al. (2005) IDO and interferon-alphainduced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry10: 538-544.
13. Yirmiya R, (1996) Endotoxin produces a depressive-like episode in rats. Brain Res 711: 163-174.
14. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB, (2006) A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol 6: 903-907.
15. Fiese EF, Steffen SH (1990) Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 25(Suppl. A): 39-47.
16. Foulds G, Shepard RM, Johnson RB (1990) The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25(Suppl. A): 73-82.
17. Girard AE. Girard AR, English TD, Gooz CR, Cimochowski JA, et al. (1987) Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 31: 1948-1954.
18. Scaglione F, Rossoni G (1998) Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 41 Suppl B: 47-50.
19. Ivetić Tkalcević V, Bosnjak B, Hrvacić B, Bosnar M, Marjanović N, et al. (2006) Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol 539: 131-138.
20. Rajman I, (2008) PK/PD modelling and simulations: utility in drug development. Drug Discov Today 13: 341-346.
21. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, et al. (2007) Model-based drug development. Clin Pharmacol Ther 82: 21-32.
22. Ohtani M, Kotaki H, Sawada Y, Iga T, (1995) Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based onpharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 272: 505-510.
23. Yassen A, Olofsen E, Dahan A, Danhof M, (2005) Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 313: 1136-1149.
24. Mormede C, Palin K, Kelley KW, Castanon N, Dantzer R, (2004) Conditioned taste aversion with lipopolysaccharide and peptidoglycan does not activate cytokine gene expression in the spleen and hypothalamus of mice. Brain Behav Immun18: 186-200.
25. Lestage J, Verrier D, Palin K, Dantzer R, (2002) The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav Immun 16: 596-601.
26. Barrett B, Borek-Dohalský V, Fejt P, Vaingátová S, Huclová J, et al. (2005) Validated HPLC-MS-MS method for determination of azithromycin in human plasma. Anal Bioanal Chem 383: 210-217.
27. Porsolt RD, Bertin A, Jalfre M, (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327-336.
28. Pechnick RN, Chesnokova VM, Kariagina A, Price S, Bresee CJ, et al. (2004) Reduced immobility in the forced swim test in mice with a targeted deletion of the leukemia inhibitory factor (LIF) gene. Neuropsychopharmacology 29: 770-776.
29. Svenningsson P, Tzavara ET, Qi H, Carruthers R, Witkin JM, et al. (2007) Biochemical and behavioral evidence for antidepressant like effects of 5-HT6 receptor stimulation. J Neurosci 27: 4201-4209.
30. Watanabe S, Kanada S, Takenaka M, Hamazaki T, (2004) Dietary n-3 fatty acids selectively attenuate LPS-induced behavioral depression in mice. Physiol Behav 81: 605-613.
31. Dayneka NL, Garg V, Jusko WJ, (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21: 457-478.
32. Aubert JD, Juillerat-Jeanneret L, Fioroni P, Dayer P, Plan PA, et al. (1998) Function of human alveolar macrophages after a 3-day course of azithromycin in healthy volunteers. Pulm Pharmacol Ther 11: 263-269.
33. Sun YN, Jusko WJ, (1998) Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 87: 732-737.
34. D'Argenio DZ, Schumitzky A (1997) ADAPT II User's Guide. Biomedical Simulations Resource. Los Angeles: University of Southern California. 316 p.
35. Kronenberg S, Frisch A, Rotberg B, Carmel M, Apter A, et al. (2008) Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety. Pharmacogenomics 9: 1725-1736.
36. Homberg JR, Schubert D, Gaspar P, (2010) New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 31: 60-65.
37. Fuller-Thomson E, Sulman J, (2006) Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 12: 697-707.
38. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, et al. (2002) Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 7: 468-473.
39. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW, (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9: 46-56.
40. Dantzer R, Kelley KW, (2007) Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 21: 153-160.
41. Steinman L, (2008) Nuanced roles of cytokines in three major human brain disorders. J Clin Invest 118: 3557-3563.
42. Gal EM, Sherman AD, (1980) 1-Kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 5: 223-239.
43. Heyes MP, Saito K, Major EO, Milstien S, Markey SP, et al. (1993) A mechanism of quinolinic acid formation by brain in inflammatory neurologic disease: attenuation of synthesis from 1-tryptophan by 6-chloro-tryptophan and 4-chloro- 3-hydroxyanthranilate. Brain 116: 1425-1450.
44. Shapiro L, Gelfand JA, (1993) Cytokines and sepsis: pathophysiology and therapy. New Horiz 1: 13-22.
45. Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, et al. (2006) The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 139: 655-662.
46. Muller N, Schwarz MJ, (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12: 988-1000.
47. Schwarcz R, (2004) The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 4: 12-17.
48. Amsden GW, (2005) Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 55: 10-21.
49. Culic O, Erakovic V, Parnham MJ, (2001) Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 429: 209-229.
50. Azoulay-Dupuis E, Vallée JP, Bedos M, Muffat J, Pocilado JJ, (1991) Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother 35: 1024-1028.
51. Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, et al. (2002) Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 49: 745-755.
52. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, et al. (2008) Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation 13: 5-15.
53. Josa M, Urizar JP, Rapado J, Dios-Viéitez C, Castañeda-Hernández G, et al. (2001) Pharmacokinetic/pharmacodynamic modeling of antipyretic and anti-inflammatory effects of naproxen in the rat.J Pharmacol Exp Ther. 297: 198-205.
54. Chen Y, Cao Y, Zhou J, Liu X, (2009) Mechanism based pharmacokinetic pharmacodynamic modeling of bidirectional effect ofdanshensu on plasma homocysteine in rats. Pharm Res 26: 1863-1873.
55. De Lange EC, Ravenstijn PG, Groenendaal D, van Steeg TJ, (2005) Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J 7: E532-543.